SCHEMBL2170779

SCHEMBL2170779

O=Cc1nc(Br)ccc1Br

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.31
TRIM33 Q9UPN9 1/20 0.31
CCR1 P32246 1/20 0.31
ERN1 O75460 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1584446 0.79 ALDH1A1 (0.35) CCR1
SCHEMBL15990229 0.79 ERN1 (0.41) TRIM24TRIM33ERN1
SCHEMBL30139595 0.79 ERN1 (0.32) ERN1
SCHEMBL1574793 0.79
SCHEMBL840004 0.79 ERN1 (0.32) ERN1
SCHEMBL24609032 0.79 RRM2 (0.45)
SCHEMBL29706502 0.79 ALDH1A1 (0.35) CCR1
SCHEMBL31337139 0.79 ALDH1A1 (0.32)
SCHEMBL22342564 0.79 ALDH1A1 (0.32)
SCHEMBL15927725 0.76 CCR1 (0.37) CCR1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636279-B2 Choline salt forms of an HIV capsid inhibitor GILEAD SCIENCES, INC. (US) 2026-05-26 US disclosed
CN-116854630-B Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2026-05-19 CN disclosed
US-12594267-B2 Capsid inhibitors for the treatment of HIV GILEAD SCIENCES, INC. (US) 2026-04-07 US disclosed
US-12492189-B2 Solid forms of an HIV capsid inhibitor GILEAD SCIENCES, INC. (US) 2025-12-09 US disclosed
CN-120078775-A Capsid inhibitors for the treatment of HIV 吉利德科学公司 2025-06-03 CN disclosed
CN-120053445-A Capsid inhibitors for the treatment of HIV 吉利德科学公司 2025-05-30 CN disclosed
CN-120053446-A Capsid inhibitors for the treatment of HIV 吉利德科学公司 2025-05-30 CN disclosed
CN-120053447-A Capsid inhibitors for the treatment of HIV 吉利德科学公司 2025-05-30 CN disclosed
CN-119954778-A Synthesis method of lenacipam sodium and series of intermediate compounds thereof 杭州科巢生物科技有限公司 2025-05-09 CN disclosed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US disclosed
WO-2014110297-A1 (HETERO) ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2014-07-17 WO disclosed
WO-2014110297-A1 (HETERO) ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2014-07-17 WO disclosed
US-8283358-B2 N-sulfonamido polycyclic pyrazolyl compounds ELAN PHARMACEUTICALS, INC. (US) 2012-10-09 US disclosed
US-8283358-B2 N-sulfonamido polycyclic pyrazolyl compounds ELAN PHARMACEUTICALS, INC. (US) 2012-10-09 US disclosed
US-8283358-B2 N-sulfonamido polycyclic pyrazolyl compounds ELAN PHARMACEUTICALS, INC. (US) 2012-10-09 US disclosed
EP-2346863-A2 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS Elan Pharmaceuticals Inc. (US) 2011-07-27 EP disclosed
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. 2010-04-01 US disclosed
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. 2010-04-01 US disclosed
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. 2010-04-01 US disclosed
WO-2010028213-A2 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636279-B2 Choline salt forms of an HIV capsid inhibitor CHKA, SLC5A7, SLC44A1 TRIM24 1237/4885TRIM33 1918/4885CCR1 165/4885
US-12594267-B2 Capsid inhibitors for the treatment of HIV CTDSP1, POLR2H, POLR2E TRIM24 560/4885TRIM33 270/4885CCR1 1122/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 TRIM24 4841/4885TRIM33 4856/4885CCR1 448/4885
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS PSEN1, PSEN2, SULT1E1 TRIM24 4386/4885TRIM33 4446/4885CCR1 1736/4885
US-12492189-B2 Solid forms of an HIV capsid inhibitor ZC3HAV1, GTF3C3, ZC3HAV1L TRIM24 697/4885TRIM33 1693/4885CCR1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.